Chilblain lupus 1
disease diseaseOn this page
Also known as CHBL1chilblain lupuschilblain lupus caused by mutation in TREX1chilblain lupus type 1TREX1 chilblain lupus
Summary
Chilblain lupus 1 (MONDO:0012500) is a disease caused by TREX1 (GenCC Strong), with 3 cohort genes.
At a glance
- Causal gene: TREX1 (GenCC Strong)
- Cohort genes: 3
- ClinVar variants: 539
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | chilblain lupus 1 |
| Mondo ID | MONDO:0012500 |
| OMIM | 610448 |
| UMLS | C0024145 |
| MedGen | 9822 |
| GARD | 0018493 |
| Is cancer (heuristic) | no |
Also known as: CHBL1 · chilblain lupus · chilblain lupus 1 · chilblain lupus caused by mutation in TREX1 · chilblain lupus type 1 · TREX1 chilblain lupus
Data availability: 539 ClinVar variants · 3 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › autoimmune disorder of cardiovascular system › chilblain lupus › familial chilblain lupus › chilblain lupus 1
Related subtypes (1): chilblain lupus 2
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
539 retrieved; paginated sample, class counts are floors:
321 uncertain significance, 133 likely benign, 29 pathogenic, 25 conflicting classifications of pathogenicity, 17 pathogenic/likely pathogenic, 6 likely pathogenic, 5 benign, 3 benign/likely benign
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 1068732 | NC_000003.11:g.(?48507870)(50340407_?)del | AMIGO3 | Pathogenic | criteria provided, single submitter |
| 1069131 | NM_033629.6(TREX1):c.403C>T (p.Gln135Ter) | ATRIP | Pathogenic | criteria provided, single submitter |
| 1069943 | NM_033629.6(TREX1):c.123_125dup (p.Cys42Ter) | ATRIP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1216160 | NM_033629.6(TREX1):c.144del (p.Thr49fs) | ATRIP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 126386 | NM_033629.6(TREX1):c.366_368dup (p.Ala123_His124insAla) | ATRIP | Pathogenic | criteria provided, single submitter |
| 126389 | NM_033629.6(TREX1):c.500del (p.Ser167fs) | ATRIP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 126390 | NM_033629.6(TREX1):c.58dup (p.Glu20fs) | ATRIP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1299626 | NM_033629.6(TREX1):c.137dup (p.Ser46fs) | ATRIP | Pathogenic/Likely pathogenic | criteria provided, single submitter |
| 1333993 | NM_033629.6(TREX1):c.621_622del (p.Ile207fs) | ATRIP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1430592 | NM_033629.6(TREX1):c.153_166del (p.Gln51fs) | ATRIP | Pathogenic | criteria provided, single submitter |
| 1433355 | NM_033629.6(TREX1):c.296_299dup (p.Phe100fs) | ATRIP | Pathogenic | criteria provided, single submitter |
| 1455316 | NM_033629.6(TREX1):c.5del (p.Gly2fs) | ATRIP | Pathogenic | criteria provided, single submitter |
| 1690729 | NM_033629.6(TREX1):c.150_151del (p.Gln51fs) | ATRIP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2127740 | NM_033629.6(TREX1):c.18dup (p.Pro7fs) | ATRIP | Pathogenic | criteria provided, single submitter |
| 225499 | NM_033629.6(TREX1):c.294dup (p.Cys99fs) | ATRIP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 282766 | NM_033629.6(TREX1):c.144dup (p.Thr49fs) | ATRIP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 282767 | NM_033629.6(TREX1):c.152_153del (p.Gln51fs) | ATRIP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2930302 | NM_033629.6(TREX1):c.226_233dup (p.Ser78fs) | ATRIP | Pathogenic | criteria provided, single submitter |
| 2936844 | NM_033629.6(TREX1):c.349C>T (p.Gln117Ter) | ATRIP | Pathogenic | criteria provided, single submitter |
| 2936991 | NM_033629.6(TREX1):c.522_523delinsTT (p.Arg174_Lys175delinsSerTer) | ATRIP | Pathogenic | criteria provided, single submitter |
| 2942588 | NM_033629.6(TREX1):c.205_206del (p.Leu69fs) | ATRIP | Pathogenic | criteria provided, single submitter |
| 2942595 | NM_033629.6(TREX1):c.371_381del (p.His124fs) | ATRIP | Pathogenic | criteria provided, single submitter |
| 2944466 | NM_033629.6(TREX1):c.76_80dup (p.Gln28fs) | ATRIP | Pathogenic | criteria provided, single submitter |
| 2945896 | NM_033629.6(TREX1):c.69dup (p.Pro25fs) | ATRIP | Pathogenic | criteria provided, single submitter |
| 2947312 | NM_033629.6(TREX1):c.565C>T (p.Gln189Ter) | ATRIP | Pathogenic | criteria provided, single submitter |
| 2948275 | NM_033629.6(TREX1):c.366_367del (p.Ala123fs) | ATRIP | Pathogenic | criteria provided, single submitter |
| 2952190 | NM_033629.6(TREX1):c.141_151del (p.Pro48fs) | ATRIP | Pathogenic | criteria provided, single submitter |
| 4179 | NM_033629.6(TREX1):c.341G>A (p.Arg114His) | ATRIP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4180 | NM_033629.6(TREX1):c.490C>T (p.Arg164Ter) | ATRIP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4184 | NM_033629.6(TREX1):c.598G>A (p.Asp200Asn) | ATRIP | Pathogenic | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 17 · Orphanet: 5 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| TREX1 | Strong | Autosomal dominant | chilblain lupus 1 | 17 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| TREX1 | Orphanet:247691 | Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations |
| TREX1 | Orphanet:481662 | Familial Chilblain lupus |
| TREX1 | Orphanet:51 | Aicardi-Goutières syndrome |
| TREX1 | Orphanet:536 | Systemic lupus erythematosus |
| ATRIP | Orphanet:808 | Seckel syndrome |
Cohort genes → proteins
3 cohort genes, 3 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 3 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| TREX1 | HGNC:12269 | ENSG00000213689 | Q9NSU2 | Three-prime repair exonuclease 1 | gencc,clinvar |
| AMIGO3 | HGNC:24075 | ENSG00000176020 | Q86WK7 | Amphoterin-induced protein 3 | clinvar |
| ATRIP | HGNC:33499 | ENSG00000164053 | Q8WXE1 | ATR-interacting protein | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| TREX1 | Three-prime repair exonuclease 1 | Major cellular 3’-to-5’ DNA exonuclease which digests single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) with mismatched 3’ termini. |
| AMIGO3 | Amphoterin-induced protein 3 | May mediate heterophilic cell-cell interaction. |
| ATRIP | ATR-interacting protein | Required for checkpoint signaling after DNA damage. |
Protein-family classification
Druggable: 2 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.67
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Antibody/Immunoglobulin | 1 | 9.7× | 0.298 |
| Enzyme (other) | 1 | 4.0× | 0.345 |
| Other/Unknown | 1 | 0.6× | 0.914 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| TREX1 | Enzyme (other) | yes | 3.1.11.2 | RNaseH-like_sf, Ribonucl_H, RNaseH_sf |
| AMIGO3 | Antibody/Immunoglobulin | yes | Leu-rich_rpt, Leu-rich_rpt_typical-subtyp, Ig_sub2 | |
| ATRIP | Other/Unknown | no | ATRIP |
Expression context
Cohort genes with no expression data: 0.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 3 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| granulocyte | 1 |
| leukocyte | 1 |
| olfactory segment of nasal mucosa | 1 |
| hindlimb stylopod muscle | 1 |
| primordial germ cell in gonad | 1 |
| stromal cell of endometrium | 1 |
| left testis | 1 |
| right testis | 1 |
| testis | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| TREX1 | 134 | ubiquitous | yes | olfactory segment of nasal mucosa, granulocyte, leukocyte |
| AMIGO3 | 129 | broad | yes | primordial germ cell in gonad, hindlimb stylopod muscle, stromal cell of endometrium |
| ATRIP | 170 | ubiquitous | yes | left testis, right testis, testis |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| ATRIP | 1,544 |
| TREX1 | 1,214 |
| AMIGO3 | 778 |
Structural data
PDB: 2 · AlphaFold-only: 1 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| TREX1 | Q9NSU2 | 12 |
| ATRIP | Q8WXE1 | 11 |
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| AMIGO3 | Q86WK7 | 73.90 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 28. Enrichment computed across 3 evidence-associated genes (2 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Regulation by TREX1 | 1 | 5710.0× | 0.005 | TREX1 |
| IRF3-mediated induction of type I IFN | 1 | 407.9× | 0.016 | TREX1 |
| Diseases of DNA Double-Strand Break Repair | 1 | 407.9× | 0.016 | ATRIP |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | 1 | 407.9× | 0.016 | ATRIP |
| Diseases of DNA repair | 1 | 285.5× | 0.016 | ATRIP |
| Homologous DNA Pairing and Strand Exchange | 1 | 190.3× | 0.016 | ATRIP |
| Homology Directed Repair | 1 | 154.3× | 0.016 | ATRIP |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 1 | 154.3× | 0.016 | ATRIP |
| Impaired BRCA2 binding to RAD51 | 1 | 154.3× | 0.016 | ATRIP |
| Activation of ATR in response to replication stress | 1 | 150.3× | 0.016 | ATRIP |
| HDR through Single Strand Annealing (SSA) | 1 | 146.4× | 0.016 | ATRIP |
| Fanconi Anemia Pathway | 1 | 139.3× | 0.016 | ATRIP |
| Presynaptic phase of homologous DNA pairing and strand exchange | 1 | 135.9× | 0.016 | ATRIP |
| DNA Double-Strand Break Repair | 1 | 124.1× | 0.016 | ATRIP |
| HDR through Homologous Recombination (HRR) | 1 | 95.2× | 0.020 | ATRIP |
| G2/M Checkpoints | 1 | 67.2× | 0.024 | ATRIP |
| Regulation of TP53 Activity | 1 | 66.4× | 0.024 | ATRIP |
| G2/M DNA damage checkpoint | 1 | 60.1× | 0.024 | ATRIP |
| Regulation of TP53 Activity through Phosphorylation | 1 | 58.9× | 0.024 | ATRIP |
| Processing of DNA double-strand break ends | 1 | 57.1× | 0.024 | ATRIP |
| DNA Repair | 1 | 49.2× | 0.027 | ATRIP |
| Cell Cycle Checkpoints | 1 | 44.3× | 0.029 | ATRIP |
| Transcriptional Regulation by TP53 | 1 | 31.0× | 0.039 | ATRIP |
| Cell Cycle | 1 | 18.0× | 0.064 | ATRIP |
| RNA Polymerase II Transcription | 1 | 11.3× | 0.097 | ATRIP |
| Gene expression (Transcription) | 1 | 8.9× | 0.117 | ATRIP |
| Generic Transcription Pathway | 1 | 7.5× | 0.133 | ATRIP |
| Disease | 1 | 6.5× | 0.147 | ATRIP |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| immune response in brain or nervous system | 1 | 5617.3× | 0.004 | TREX1 |
| immune complex formation | 1 | 5617.3× | 0.004 | TREX1 |
| activation of immune response | 1 | 2808.7× | 0.004 | TREX1 |
| DNA modification | 1 | 2808.7× | 0.004 | TREX1 |
| DNA synthesis involved in UV-damage excision repair | 1 | 2808.7× | 0.004 | TREX1 |
| retrotransposition | 1 | 1872.4× | 0.005 | TREX1 |
| atrial cardiac muscle tissue development | 1 | 1404.3× | 0.005 | TREX1 |
| T cell antigen processing and presentation | 1 | 1123.5× | 0.005 | TREX1 |
| lymphoid progenitor cell differentiation | 1 | 936.2× | 0.005 | TREX1 |
| regulation of cellular respiration | 1 | 936.2× | 0.005 | TREX1 |
| regulation of lipid biosynthetic process | 1 | 936.2× | 0.005 | TREX1 |
| regulation of lysosome organization | 1 | 936.2× | 0.005 | TREX1 |
| DNA repair | 2 | 42.6× | 0.005 | TREX1, ATRIP |
| regulation of immunoglobulin production | 1 | 802.5× | 0.005 | TREX1 |
| heart process | 1 | 702.2× | 0.005 | TREX1 |
| regulation of fatty acid metabolic process | 1 | 624.1× | 0.005 | TREX1 |
| regulation of T cell activation | 1 | 624.1× | 0.005 | TREX1 |
| regulation of type I interferon production | 1 | 561.7× | 0.005 | TREX1 |
| regulation of tumor necrosis factor production | 1 | 561.7× | 0.005 | TREX1 |
| cellular response to hydroxyurea | 1 | 468.1× | 0.006 | TREX1 |
| regulation of glycolytic process | 1 | 401.2× | 0.006 | TREX1 |
| macrophage activation involved in immune response | 1 | 374.5× | 0.006 | TREX1 |
| DNA metabolic process | 1 | 351.1× | 0.006 | TREX1 |
| mitotic G1 DNA damage checkpoint signaling | 1 | 351.1× | 0.006 | TREX1 |
| regulation of protein complex stability | 1 | 351.1× | 0.006 | TREX1 |
| negative regulation of cGAS/STING signaling pathway | 1 | 351.1× | 0.006 | TREX1 |
| inflammatory response to antigenic stimulus | 1 | 312.1× | 0.006 | TREX1 |
| DNA catabolic process | 1 | 312.1× | 0.006 | TREX1 |
| apoptotic cell clearance | 1 | 295.6× | 0.006 | TREX1 |
| negative regulation of type I interferon-mediated signaling pathway | 1 | 255.3× | 0.007 | TREX1 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 2
Druggability breadth: 1 of 3 evidence-associated genes (33%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| ATRIP | 3 | 3 |
| TREX1 | 0 | 0 |
| AMIGO3 | 0 | 0 |
Drugs targeting cohort genes (top 30)
| Molecule | Max phase | Targets in cohort |
|---|---|---|
| CERALASERTIB | 3 | ATRIP |
| ELIMUSERTIB | 1 | ATRIP |
| M4344 | 1 | ATRIP |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 1.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| ATRIP | 31 | Binding:31 |
Cohort enzymes (BRENDA EC)
| Symbol | EC numbers | Names |
|---|---|---|
| TREX1 | 3.1.11.2 | exodeoxyribonuclease III |
Pharmacogenomics
Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
3 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
| Compound | Max phase | Cohort target (bioactivity) |
|---|---|---|
| CERALASERTIB | 3 | ATRIP |
| ELIMUSERTIB | 1 | ATRIP |
| M4344 | 1 | ATRIP |
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 1 | ATRIP |
| C | Druggable family + PDB, no drug | 1 | TREX1 |
| D | Druggable family + AlphaFold only, no drug | 1 | AMIGO3 |
| E | Difficult family or no structure, no drug | 0 |
Undrugged target profiles
2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| TREX1 | 0 | — |
| AMIGO3 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.